Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13807838 | 0.93 | CNR1 (0.56) | HTTPOLBNPC1KMT2AMEN1 | |
| SCHEMBL13807836 | 0.88 | NPC1 (0.56) | HTTPOLBNPC1KMT2AMEN1 | |
| SCHEMBL5054147 | 0.84 | KMT2A (0.54) | HTTPOLBNPC1KMT2AMEN1 | |
| SCHEMBL5058752 | 0.83 | CNR1 (0.59) | HTTPOLBNPC1KMT2AMEN1 | |
| SCHEMBL5054318 | 0.83 | MEN1 (0.62) | HTTPOLBNPC1KMT2AMEN1 | |
| SCHEMBL5057347 | 0.82 | MEN1 (0.61) | HTTPOLBNPC1KMT2AMEN1 | |
| SCHEMBL5058781 | 0.82 | MEN1 (0.61) | NPC1KMT2AMEN1LMNATP53 | |
| SCHEMBL14206085 | 0.78 | MEN1 (0.69) | POLBNPC1KMT2AMEN1TP53 | |
| SCHEMBL5057201 | 0.75 | MEN1 (0.57) | POLBNPC1KMT2AMEN1LMNA | |
| SCHEMBL5057283 | 0.75 | CNR1 (0.63) | NPC1KMT2AMEN1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | ACADIA PHARMACEUTICALS | 2007-05-10 | — | — | US | disclosed |
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | SDHB, TFRC, SLC40A1 | HTT 4059/4885POLB 1159/4885NPC1 1027/4885 |
| US-20070105819-A1 | CB-1 modulating compounds and their use | CNR1, CNR2, FAAH | HTT 3941/4885POLB 4785/4885NPC1 225/4885 |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | CNR1, CNR2, FAAH | HTT 3941/4885POLB 4785/4885NPC1 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.